FUNDAMENTALS · Fundamentals · US Healthcare

Neuphoria Therapeutics (NEUP) Fundamentals 2026 — Revenue Analysis | SniperIQ

Neuphoria Therapeutics (NEUP) is a US-listed Healthcare company in Biotechnology with a market capitalization of

8M, trading at
.31 on the NASDAQ. This SniperIQ fundamentals page covers Neuphoria Therapeutics's valuation, profitability (net margin 272.0%), revenue (
6M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
8M
Net Margin272.0%
Revenue (FY25)
6M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Neuphoria Therapeutics's market cap?

Neuphoria Therapeutics (NEUP) has a market capitalization of approximately

8M, trading at
.31 on the NASDAQ. Market cap moves with the live share price.

What is Neuphoria Therapeutics's P/E ratio?

Neuphoria Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Neuphoria Therapeutics?

Neuphoria Therapeutics runs a net profit margin of 272.0%, a gross margin of 104.7%, and an operating margin of 230.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Neuphoria Therapeutics generate?

Neuphoria Therapeutics reported revenue of

6M for fiscal year 2025, with net income of -
69,632 and earnings per share (EPS) of -0.23. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Neuphoria Therapeutics pay a dividend?

Neuphoria Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Neuphoria Therapeutics financially healthy?

Neuphoria Therapeutics carries a debt-to-equity ratio of 0.00x and a current ratio of 14.31x, with a market beta of 0.75. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Neuphoria Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Neuphoria Therapeutics (NEUP) the key facts are: market cap

8M, revenue
6M, 52-week range 3.19-21.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Neuphoria Therapeutics's full fundamentals live

Get Neuphoria Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Jin Medical International (ZJYL) fundamentals · Aytu BioPharma (AYTU) fundamentals · Werewolf Therapeutics (HOWL) fundamentals · ABVC BioPharma (ABVC) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons